Benjamin McDonald

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Year:

2026

Year:

2026

INTRODUCTION: Janus kinase inhibitors (JAKi) are small-molecule therapies used in inflammatory bowel disease (IBD). We describe 8 patients with IBD who developed an eczematous eruption, presumed atopic dermatitis (AD), after stopping JAKi therapy. METHODS: This case series describes 8 patients with IBD who developed de novo AD after withdrawal of JAKi therapy. RESULTS: Median time to AD onset was 7 days (interquartile range 2–12). Two cases with biopsy-confirmed AD resolved after reinitiation of JAKi therapy and adjunct AD treatments. DISCUSSION: A subset of patients with IBD may have latent susceptibility to AD, unmasked by therapy cessation and potentially triggered by an immune rebound effect.

Year:

2025

Year:

2024

Year:

2022

Collaborators (6)

Alex J Mathew

Research Director (Rubin Lab)

University of Chicago

UNITED STATES
View details

David Choi

University of Chicago Medicine

UNITED STATES
View details

Angad Chadha

Physician / Asst Prof

University of Chicago

UNITED STATES
View details

Christopher Shea

Professor

University of Chicago

UNITED STATES
View details

Joel Pekow

-

UNITED STATES
View details

David Rubin

Professor

University of Chicago

UNITED STATES
View details